Maggie L. Shaw

Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.

Innovation in the specialty pipeline, drug costs, health care policy updates, and collaboration were key topics at this year's Asembia Specialty Pharmacy Summit.

In part 2 of our interview with Binod Dhakal, MD, he addresses how CARTITUDE-4 study findings help to advance the clinical understanding of ciltacabtagene autoleucel (cilta-cel) and the importance of vigilance and education on the treatment’s adverse effects.

In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.

Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.

In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.

Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.

Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.

Third-party tracking technologies are at the heart of a new analysis, which investigated if hospital websites accurately disclose how they transmit user information to third parties.

To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.

Just as it is important for retail analysts to understand the choices their customers make and why they may choose not to purchase a specific item, so is it important for the specialty pharmacy industry to understand the actions of prescribers and how the often inefficient prior authorization process affects patient outcomes.

This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.

Asembia AXS24, which has record registration this year, will take place in Las Vegas, Nevada, April 28-May 2, at the Wynn & Encore Las Vegas.

Coverage from the Community Oncology Alliance Community Oncology Conference, held April 4-5, 2024, in Orlando, Florida.

New guidance on managing desmoid fibromatosis recommends a more conservative approach, encompassing the patient perspective, active surveillance, tumor location, and risk-benefit assessment.

Diabetes treatment goals vary based on age and diabetes type, with more focus on managing insulin levels for children and adolescents while addressing comorbid conditions like obesity and hypertension for adults, said Beau Raymond, MD, MMM, FACP, of Ochsner Health Network.

Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, from which data were used by the FDA to approve ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy.

To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.

The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.

Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP, highlights the biggest threats concerning a cyberattack on oncology practices.

Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy.

In this retrospective analysis, outcomes data were evaluated on patients receiving care related to extrapleural pneumonectomy for soft tissue sarcoma or bone sarcoma.

Beau Raymond, MD, MMM, FACP, chief medical officer of Ochsner Health Network, explains the importance of diabetes and hypertension control to prevent downstream events such as heart attacks and strokes.

Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), discusses upcoming policy initiatives and the current oncology landscape amid a health care cyberattack.

Public health campaigns are imperative to alleviating food insecurity, Pat Van Burkleo, executive director of Feeding Louisiana, the Louisiana Food Bank Association, explained in an interview.

The data for this analysis on survivors of lung cancer came from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center thoracic oncology clinics.

In this interview from our coverage of the 2024 Community Oncology Conference, Shawn Tuma, JD, CIPP/US, Spencer Fane LLP, discusses how he helps clients reduce their cyber risk and be better prepared for breaches when they occur.

To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.

Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.

Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.